This aligns with previous research indicating that aberrant PI3K-Akt signaling contributes to aggressive breast cancer phenotypes and poor patient outcomes (Cancer Genome Atlas Network, 2012; Tian et al., 2021; Guo et al., 2023). This evidence concerns the gene AKT1 and breast cancer.